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a  b  s  t  r  a  c  t
INTRODUCTION:  Synchronous  gynecologic  primary  cancers  are  uncommon.  When  present,  the  most  fre-
quent malignancies  consist  of  endometrial  and  ovarian  carcinomas.  Here  we  report  an  exceedingly  rare
case  of concurrent  uterine  adenocarcinoma  and  leiomyosarcoma.
CASE  PRESENTATION:  A  60 year-old  female  presented  with  four years  of  postmenopausal  bleeding.  An
endometrial  sampling  showed  grade  2 endometrioid  adenocarcinoma.  She  proceeded  with  hysterec-
tomy  that  contained  an  anterior  endometrial  mass  and  a posterior  myometrial  mass.  The  ﬁnal  pathology
demonstrated  concurrent  uterine  adenocarcinoma  and  leiomyosarcoma.
DISCUSSION:  To the  best of our  knowledge,  this  is the third  reported  case  of  simultaneous  uterine  adeno-
carcinoma  and  leiomyosarcoma.  As this  presentation  is infrequent  with  limited  literature,  this  caused  aeiomyosarcoma clinical  management  conundrum.  Unfortunately,  the follow-up  PET  scan  suggested  possible  recurrence
or metastasis  three  months  after  the  surgery.
CONCLUSION:  Simultaneous  uterine  adenocarcinoma  and  leiomyosarcoma  is  an  exceptionally  rare  event.
As the experience  is  limited,  a multidisciplinary  approach  in  managing  these  patients  may  be  the  best
option  currently  available.
©  2016  The  Authors.  Published  by  Elsevier  Ltd.  on behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
Prevalence of multiple gynecologic cancers is only approxi-
ately 1% with endometrial and ovarian carcinomas being most
requently observed [1–3]. While concomitant primary malignan-
ies have been encountered for over a century, our understanding
f the etiology and management for simultaneous tumors remains
nclear. Here we  report an exceedingly rare case of hysterectomy
nd bilateral salpingo-oophorectomy with concurrent uterine
denocarcinoma, leiomyosarcoma and bilateral serous cystade-
oﬁbromas.
. Case presentationA 60 year-old female smoker with multiple co-morbidities pre-
ented with postmenopausal bleeding for four years. Endometrial
ampling revealed a grade 2 endometrioid type adenocarcinoma,
nd the patient underwent total abdominal hysterectomy and bilat-
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eral salpingo-oophorectomy. At the time of surgery, there was  no
evidence of omental or abdominal disease; therefore, no additional
staging was performed due to patient’s co-morbidities.
Grossly, within the anterior endometrium was  a 7.2 cm fun-
gating hemorrhagic mass that invaded the outer half of the
myometrium and extended down to the endocervix. Addition-
ally, in the posterior myometrium was a 10.5 cm tan to yellow,
soft intramural mass that is completely separate from the ante-
rior endometrial tumor. Within this mass was a softer region
(5.1 cm)  that contained a focal area of necrosis. The bilateral
ovaries were enlarged and cystic (left = 7.1 cm and right = 4.2 cm)
and the bilateral fallopian tubes were unremarkable. Incidentally
discovered was  a 2.2 cm nodule in the right meso-ovarian soft tis-
sue. Histologically, the anterior endometrium was  involved by a
grade 2 endometrioid adenocarcinoma that invaded 92% of the
myometrium and extended to the cervical stromal connective
tissue (Fig. 1). The incidentally found meso-ovarian nodule was
histologically consistent with metastatic endometrioid adenocarci-
noma. Interestingly, the posterior large myometrial mass consisted
of predominantly leiomyoma (Fig. 2A). However, within this mass
was a region of tumor cells with bizarre pleomorphic nuclei and
numerous mitoses including atypical forms (Fig. 2B). Immunohis-
tochemistry was  positive for smooth muscle actin and desmin,
supporting the diagnosis of leiomyosarcoma. While a diagnosis of
carcinosarcoma was  considered, the two malignancies involved dif-
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wig. 1. Endometrial adenocarcinoma (upper left) invading the cervical stromal con-
ective tissue. Benign endocervical tissue can be seen in the lower right.
erent sides of the uterus and were completely separate from each
ther; therefore, they were best classiﬁed by their own  entities. The
nlarged bilateral ovaries comprised of serous cystadenoﬁbromas.
. Discussion
Simultaneous primary neoplasms are uncommon and not well
nderstood. While concurrent endometrial and ovarian cancers are
ost frequently encountered in gynecologic oncology, only two
ther cases of concomitant endometrial adenocarcinoma and uter-
ne leiomyosarcoma have been reported in the English literature
4,5]. Sheyn et al. published the ﬁrst patient with simultaneous ade-
ocarcinoma and leiomyosarcoma of the uterus [5]. A later report
escribed similar ﬁndings with the addition of ovarian mucinous
denocarcinoma [4]. Our patient has the two unusual synchronous
alignancies previously described with bilateral serous cystade-
oﬁbromas.
In cases where epithelial and mesenchymal malignancies
o-exist, the more commonly encountered uterine malignancy, car-
inosarcoma, has to be considered. Carcinosarcoma accounts for
5% of all uterine malignancies and the diagnosis is made based on
 mixture of high-grade carcinomatous and sarcomatous elements
n the same lesion. Although our case contained both epithelial and
esenchymal malignancies, grossly these two lesions were located
t different sides of the uterus and were histologically distinct from
ach other. For these reasons, two different primary diagnoses were
endered. This is an important distinction as clinical management
or carcinosarcoma would differ.
ig. 2. (A) Low power image of leiomyosarcoma (left) adjacent to leiomyoma (right). (B) H
ith  atypical forms.PEN  ACCESS
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Several studies have suggested that synchronous endometrial
and ovarian primary cancers have an earlier stage and a lower
grade disease at the time of presentation, with a 25% reduc-
tion in risk of death when compared to patients with single
tumors [6–8]. Unfortunately, this improved prognosis cannot be
extrapolated for this case as experience in this rare presentation
is limited in the literature. Optimal treatment course for syn-
chronous malignancies is controversial given different regimens
would be considered depending on cancer types and stage [6].
In this case, the leiomyosarcoma is stage IB, as it is limited to
the uterus and the mass itself is over 5 cm. Clinical management
would include observation and possible chemotherapy such as
gemcitabine and docetaxel. Staging for endometrial adenocarci-
noma in this patient is incomplete given full staging was not
performed due to her co-morbidities. However, the presence of
metastatic adenocarcinoma involving the meso-ovarian soft tissue
would be considered at least stage IIIA, which would lead to radi-
ation and chemotherapy including agents such as paclitaxel and
carboplatin. This chemotherapeutic regimen differs if considering
the diagnosis of carcinosarcoma, in which case treatment includes
ifosfamide in combination with paclitaxel or cisplatin. Unfortu-
nately, three months post-surgery, the patient had a PET scan
showing abdominal and pelvic retroperitoneal lymphadenopathy,
suggesting potential metastasis. While the primary source of the
metastasis is uncertain, given her high-stage endometrial cancer,
adjuvant chemotherapy with cyclophosphamide, adriamycin and
cisplatin was  recommended [9].
Simultaneous uterine adenocarcinoma and leiomyosarcoma is
an exceedingly rare event. Given the uncommon nature of this
presentation, it is difﬁcult to know the exact disease course and
management for these patients. In this rare scenario, a multidisci-
plinary approach is extremely helpful as discussion with clinicians
with various expertise can formulate the best treatment options for
this patient.
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Consent was unable to be obtained as patient and all contacts
ere unable to be reached. IRB approval was obtained and consent
aiver provided.
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